PTC Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018 - 2011
Net Income	-626.6	-559.02	-523.9	-438.16	-251.58	Upgrade
Depreciation & Amortization	246.42	138.72	71.52	90.96	35.89	Upgrade
Share-Based Compensation	101.64	110.33	103.51	70.33	42.13	Upgrade
Other Operating Activities	120.13	-46.69	97.54	82.81	74.91	Upgrade
Operating Cash Flow	-158.42	-356.65	-251.33	-194.07	-98.64	Upgrade
Capital Expenditures	-28.44	-32.02	-28.21	-17.84	-13.76	Upgrade
Acquisitions	-89.59	-120.44	-57.22	-38.13	-35.68	Upgrade
Change in Investments	-58.71	442.64	304.61	-505.57	-337.8	Upgrade
Investing Cash Flow	-176.74	290.18	219.18	-561.55	-387.24	Upgrade
Share Issuance / Repurchase	29.99	71.08	23.1	103.57	345.61	Upgrade
Debt Issued / Paid	-383.59	137.27	-2.22	-46.76	267.6	Upgrade
Other Financing Activities	1,000	-40.4	-	611.9	-	Upgrade
Financing Cash Flow	646.4	167.95	20.88	668.72	613.21	Upgrade
Exchange Rate Effect	3.11	-2.77	-7.82	7.69	-1.3	Upgrade
Net Cash Flow	314.36	98.71	-19.09	-79.22	126.03	Upgrade
Free Cash Flow	-186.86	-388.67	-279.55	-211.91	-112.4	Upgrade
Free Cash Flow Margin	-19.92%	-55.62%	-51.90%	-55.65%	-36.61%	Upgrade
Free Cash Flow Per Share	-2.50	-5.42	-3.97	-3.21	-1.91	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).